DrugMapper
Browse
Therapeutic Area
CANCER (51)
CARDIOVASCULAR (45)
DENTISTRY (2)
DERMATOLOGY (31)
DIABETES DRUGS & ENDOCRINOLOGY (61)
EMERGENCY MEDICINE (3)
ENT (5)
EYE (23)
GASTROINTESTINAL (29)
HEMATOLOGY (23)
MUSCULOSKELETAL (28)
NEUROLOGY DRUGS & NERVOUS SYSTEM (50)
PEDIATRICS (27)
PHARMACOLOGY (8)
PREGNANCY AND GYNECOLOGY (30)
RESPIRATORY (42)
RHEUMATOLOGY (19)
OTHER (1482)
Therapeutic Indication
Adverse Reaction (System Organ Classification)
Mechanism of Action
Primary Target
Target Level
Level 1
Level 2
Level 3
Level 4
Level 5
Level 6
Active Pharmaceutical Ingredients (APIs)
Small Molecules
ProDrugs
Antibodies
CNS drugs
Metabolites
Search
Therapeutic Indication
Adverse Reaction (System Organ Classification)
Mechanism of Action
Target Sequence
Chemical Structure
Physicochemical Properties
Analyze
Networks
Chemical Similarity
Scaffold Similarity
KNIME workflow
Downloads
Web services
Bulk Downloads
About
DrugMapper FAQs
Data Sources
Contact Us
Display Options:
Drug type
Therapeutic Area
Route of administration
Mechanism of Action
Indication
Status
Total:
10647
TAPRENEPAG ISOPROPYL
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Prostanoid EP2 receptor agonist
TAPRENEPAG ISOPROPYL
×
Maximum Phase:
2
First Approval:
None
UNII:
81LDP7XIYG
Molecule Type:
Small molecule
Molecular Formula:
C27H28N4O5S
Molecular Weight:
520.61
AlogP:
3.99
PSA:
103.62
HBD:
0.0
HBA:
#RotB:
11.0
Source:
LOMIBUVIR
2
Small molecule
Investigational
Unknown
Unknown
Hepatitis C; Hepatitis C, Chronic
Hepatitis C virus NS5B RNA-dependent RNA polymerase negative allosteric modulator
LOMIBUVIR
×
Maximum Phase:
2
First Approval:
None
UNII:
37L2LF4A2D
Molecule Type:
Small molecule
Molecular Formula:
C25H35NO4S
Molecular Weight:
445.63
AlogP:
5.31
PSA:
77.84
HBD:
2.0
HBA:
#RotB:
4.0
Source:
GR205171
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
GR205171
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
CBP
2
Unknown
Investigational
Unknown
Unknown
Unknown
Unknown
CBP
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Unknown
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
SAMATASVIR
2
Small molecule
Investigational
Unknown
Unknown
Hepatitis C; Hepatitis C, Chronic
Nonstructural protein 5A inhibitor
SAMATASVIR
×
Maximum Phase:
2
First Approval:
None
UNII:
21P699C5FC
Molecule Type:
Small molecule
Molecular Formula:
C47H48N8O6S2
Molecular Weight:
885.08
AlogP:
9.37
PSA:
174.64
HBD:
4.0
HBA:
#RotB:
11.0
Source:
AZD2423
2
Small molecule
Investigational
Unknown
Unknown
Neuralgia; Pain; Pulmonary Disease, Chronic Obstructive
C-C chemokine receptor type 2 antagonist
AZD2423
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
ARTEMISIA VULGARIS
2
Unknown
Investigational
Unknown
Unknown
Unknown
Unknown
ARTEMISIA VULGARIS
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Unknown
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
C16G2
2
Unknown
Investigational
Unknown
Unknown
Dental Caries
Cell membrane disrupting agent
C16G2
×
Maximum Phase:
2
First Approval:
None
UNII:
B04Z1JB2HS
Molecule Type:
Unknown
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
UPADACITINIB TARTRATE
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
UPADACITINIB TARTRATE
×
Maximum Phase:
2
First Approval:
None
UNII:
7KCW9IQM02
Molecule Type:
Small molecule
Molecular Formula:
C21H33F3N6O11
Molecular Weight:
602.52
AlogP:
2.91
PSA:
78.32
HBD:
2.0
HBA:
#RotB:
3.0
Source:
REMTOLUMAB
2
Antibody
Investigational
Unknown
Unknown
Arthritis, Psoriatic; Arthritis, Rheumatoid
Interleukin 17A inhibitor
REMTOLUMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
1V8WRH3RVX
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
JNJ-26489112
2
Small molecule
Investigational
Unknown
Unknown
Epilepsy, Reflex
Unknown
JNJ-26489112
×
Maximum Phase:
2
First Approval:
None
UNII:
G1TI012DLT
Molecule Type:
Small molecule
Molecular Formula:
C9H11ClN2O4S
Molecular Weight:
278.72
AlogP:
0.27
PSA:
90.65
HBD:
2.0
HBA:
#RotB:
3.0
Source:
KHK-4083
2
Unknown
Investigational
Unknown
Unknown
Colitis, Ulcerative; Dermatitis, Atopic
Tumor necrosis factor receptor superfamily member 4 antagonist
KHK-4083
×
Maximum Phase:
2
First Approval:
None
UNII:
G770V925KP
Molecule Type:
Unknown
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
NADECNEMAB
2
Antibody
Investigational
Unknown
Unknown
Unknown
Unknown
NADECNEMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
LIDORESTAT
2
Small molecule
Investigational
Unknown
Unknown
Diabetic Neuropathies
Unknown
LIDORESTAT
×
Maximum Phase:
2
First Approval:
None
UNII:
R3734K0M7L
Molecule Type:
Small molecule
Molecular Formula:
C18H11F3N2O2S
Molecular Weight:
376.36
AlogP:
4.34
PSA:
55.12
HBD:
1.0
HBA:
#RotB:
4.0
Source:
GPX-100
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
GPX-100
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
DOLASTATIN 10
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
DOLASTATIN 10
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
BECOCALCIDIOL
2
Small molecule
Investigational
Unknown
Unknown
Psoriasis
Vitamin D receptor agonist
BECOCALCIDIOL
×
Maximum Phase:
2
First Approval:
None
UNII:
N75R59YD0F
Molecule Type:
Small molecule
Molecular Formula:
C23H36O2
Molecular Weight:
344.54
AlogP:
5.17
PSA:
40.46
HBD:
2.0
HBA:
#RotB:
3.0
Source:
HDI
2
Unknown
Investigational
Unknown
Unknown
Unknown
Unknown
HDI
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Unknown
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
APD371
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
APD371
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
ACORAFLOXACIN HYDROCHLORIDE
2
Small molecule
Investigational
Unknown
Unknown
Infections; Pneumonia, Bacterial
Unknown
ACORAFLOXACIN HYDROCHLORIDE
×
Maximum Phase:
2
First Approval:
None
UNII:
1NWW5SKQ0N
Molecule Type:
Small molecule
Molecular Formula:
C21H24ClF2N3O4
Molecular Weight:
455.89
AlogP:
2.96
PSA:
97.79
HBD:
2.0
HBA:
#RotB:
5.0
Source:
TREGALIZUMAB
2
Antibody
Investigational
Unknown
Unknown
Arthritis, Rheumatoid; Psoriasis
T-cell surface antigen CD4 agonist
TREGALIZUMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
43D26MK176
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
GSK2982772
2
Small molecule
Investigational
Unknown
Unknown
Immune System Diseases; Inflammatory Bowel Diseases; Arthritis, Rheumatoid; Colitis, Ulcerative; Psoriasis
Unknown
GSK2982772
×
Maximum Phase:
2
First Approval:
None
UNII:
T5W3M0VO9B
Molecule Type:
Small molecule
Molecular Formula:
C20H19N5O3
Molecular Weight:
377.4
AlogP:
1.55
PSA:
100.21
HBD:
2.0
HBA:
#RotB:
4.0
Source:
PF-04457845
2
Small molecule
Investigational
Unknown
Unknown
Chronic Pain; Tourette Syndrome; Marijuana Abuse; Osteoarthritis, Knee; Stress Disorders, Post-Traumatic
Anandamide amidohydrolase inhibitor
PF-04457845
×
Maximum Phase:
2
First Approval:
None
UNII:
H4C81M8YYW
Molecule Type:
Small molecule
Molecular Formula:
C23H20F3N5O2
Molecular Weight:
455.44
AlogP:
5.39
PSA:
80.24
HBD:
1.0
HBA:
#RotB:
4.0
Source:
TENELIXIMAB
2
Antibody
Investigational
Unknown
Unknown
Unknown
Tumor necrosis factor receptor superfamily member 5 partial agonist
TENELIXIMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
G0MV33WQ6V
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
ECROMEXIMAB
2
Antibody
Investigational
Unknown
Unknown
Melanoma
Ganglioside GD3 other
ECROMEXIMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
M76FX2JZRM
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
ADL-5859
2
Small molecule
Investigational
Unknown
Unknown
Arthritis, Rheumatoid; Osteoarthritis, Knee; Pain
Unknown
ADL-5859
×
Maximum Phase:
2
First Approval:
None
UNII:
FA554TW3UP
Molecule Type:
Small molecule
Molecular Formula:
C24H28N2O3
Molecular Weight:
392.5
AlogP:
3.82
PSA:
61.8
HBD:
2.0
HBA:
#RotB:
4.0
Source:
MAVRILIMUMAB
2
Antibody
Investigational
Unknown
Unknown
Arthritis, Rheumatoid; Giant Cell Arteritis; Severe Acute Respiratory Syndrome
Granulocyte-macrophage colony-stimulating factor receptor antagonist
MAVRILIMUMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
1158JD1P9A
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
NOX-100
2
Small molecule
Investigational
Unknown
Unknown
Hypotension
Unknown
NOX-100
×
Maximum Phase:
2
First Approval:
None
UNII:
7WFB66H4LB
Molecule Type:
Small molecule
Molecular Formula:
C8H17NO5S2
Molecular Weight:
271.36
AlogP:
-2.43
PSA:
104.39
HBD:
6.0
HBA:
#RotB:
6.0
Source:
PF-06882961
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
PF-06882961
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
TRIPLATIN TETRANITRATE
2
Small molecule
Investigational
Unknown
Unknown
Lung Neoplasms; Pancreatic Neoplasms
Unknown
TRIPLATIN TETRANITRATE
×
Maximum Phase:
2
First Approval:
None
UNII:
HAJ1000ARC
Molecule Type:
Small molecule
Molecular Formula:
C12H50Cl2N14O12Pt3
Molecular Weight:
1238.76
AlogP:
None
PSA:
None
HBD:
None
HBA:
#RotB:
None
Source:
EFATUTAZONE
2
Small molecule
Investigational
Unknown
Unknown
Multiple Myeloma; Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Liposarcoma; Thyroid Neoplasms
Unknown
EFATUTAZONE
×
Maximum Phase:
2
First Approval:
None
UNII:
M17ILL71MC
Molecule Type:
Small molecule
Molecular Formula:
C27H26N4O4S
Molecular Weight:
502.6
AlogP:
5.04
PSA:
108.47
HBD:
2.0
HBA:
#RotB:
7.0
Source:
AZD2207
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Cannabinoid CB1 receptor antagonist
AZD2207
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Small molecule
Molecular Formula:
C22H22Cl2F2N4O3+2
Molecular Weight:
499.35
AlogP:
3.67
PSA:
89.35
HBD:
4.0
HBA:
#RotB:
8.0
Source:
AZD1386
2
Small molecule
Investigational
Unknown
Unknown
Chronic Pain; Neuralgia; Pain
Vanilloid receptor antagonist
AZD1386
×
Maximum Phase:
2
First Approval:
None
UNII:
210323T9CP
Molecule Type:
Small molecule
Molecular Formula:
C19H13ClF3N3O3
Molecular Weight:
423.78
AlogP:
3.25
PSA:
78.51
HBD:
2.0
HBA:
#RotB:
2.0
Source:
ONC-201
2
Small molecule
Investigational
Unknown
Unknown
Diffuse Intrinsic Pontine Glioma; Gliosarcoma; Leukemia; Multiple Myeloma; Neoplasms; Breast Neoplasms; Endometrial Neoplasms; Glioblastoma; Glioma; Neuroendocrine Tumors
Unknown
ONC-201
×
Maximum Phase:
2
First Approval:
None
UNII:
9U35A31JAI
Molecule Type:
Small molecule
Molecular Formula:
C24H26N4O
Molecular Weight:
386.5
AlogP:
3.17
PSA:
39.15
HBD:
0.0
HBA:
#RotB:
4.0
Source:
OXALOACETATE
2
Small molecule
Investigational
Unknown
Unknown
Alzheimer Disease; Amyotrophic Lateral Sclerosis; Myasthenia Gravis; Breast Carcinoma In Situ; Parkinson Disease
Unknown
OXALOACETATE
×
Maximum Phase:
2
First Approval:
None
UNII:
2F399MM81J
Molecule Type:
Small molecule
Molecular Formula:
C4H4O5
Molecular Weight:
132.07
AlogP:
-0.89
PSA:
91.67
HBD:
2.0
HBA:
#RotB:
3.0
Source:
1
2
…
197
198
199
200
201
202
203
…
304
305
Next »
Download Option
Close
Header
Compound Name
Maximum Phase
Compound Structure
Smile
Inchi
InchiKey
Compound Properties
Molecular Formula
Molecular Weight
ALogP
PSA